Clinical trials: Dyskinesia
Tardive Dyskinesia (TD)
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
- Trial name
- NCT03698331
- Testing
- Valbenazine
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Neurocrine Biosciences
Idiopathic Parkinson Disease
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Phase 3, international, multicenter, open-label 12 month safety study.
- Trial name
- NCT03051607
- Testing
- Tozadenant
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Biotie Therapies Inc.
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Idiopathic Parkinson's Disease
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
- Trial name
- TOZ-PD (NCT02453386)
- Testing
- tozadenant
- Where
- 71 sites in United States, Austria and 5 more
- Volunteers
- 449 people
- Sponsor
- Biotie Therapies Inc.
Parkinson's Disease
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.
- Trial name
- NCT02818777
- Testing
- cannabidiol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Tardive Dyskinesia
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine (NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with TD until…
- Trial name
- NCT02736955
- Testing
- Valbenazine
- Where
- 27 sites in United States
- Volunteers
- 161 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment.
- Trial name
- Kinect 4 (NCT02405091)
- Testing
- NBI-98854
- Where
- 48 sites in United States, Canada and 1 more
- Volunteers
- 167 people
- Sponsor
- Neurocrine Biosciences
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease, Dyskinesia
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).
- Trial name
- NCT00105508
- Testing
- Sarizotan
- Where
- 31 sites in United States
- Volunteers
- 506 people
- Sponsor
- EMD Serono
Parkinson's Disease
Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).
- Trial name
- RLID-PD (NCT01563913)
- Testing
- Docosahexaenoic Acid (DHA)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease, Dyskinesia
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
- Trial name
- NCT00105521
- Testing
- Sarizotan
- Where
- 32 sites in United States
- Volunteers
- 398 people
- Sponsor
- EMD Serono
Parkinson's Disease
Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
This study is to determine if Viagra is effective in reducing dyskinesias in patients with Parkinson's Disease.
- Trial name
- NCT02162979
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Loma Linda University
Dyskinesia, Levodopa Induced Dyskinesia (LID)
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
- Trial name
- EASE LID (NCT02136914)
- Testing
- ADS-5102
- Where
- 46 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson's Disease
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements.
- Trial name
- NCT00794313
- Testing
- Amantadine 300 mg, Topiramate, Sugar Pill
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Oregon Health and Science University
Coronary Artery Disease, Acute Myocardial Ischemia
Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia
The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in acute myocardial ischemia. A pilot-trial by Venkatamaran et al.
- Trial name
- RIMINI-Pilot (NCT01797484)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Fibromyalgia, Mitochondrial Diseases
Heart Rate Variability in Response to Metformin Challenge
Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use).
- Conditions
- Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
- Trial name
- NCT02500628
- Testing
- Metformin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Woodinville Psychiatric Associates
Dyskinesia, Levodopa Induced Dyskinesia
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 4-arm parallel group study to evaluate the tolerability and efficacy of each of three dose levels of ADS-5102 oral capsules, an extended release formulation of…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
- Trial name
- EASED (NCT01397422)
- Testing
- ADS-5102 (extended release amantadine HCl)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Oral Dystonia, Tardive Dystonia
Dysport for the Treatment of OMD
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
- Trial name
- NCT01921270
- Testing
- Low Dose - AbobotulinumtoxinA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Tardive Dyskinesia
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (50 and 100 mg) of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- NCT01688037
- Testing
- NBI-98854
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 109 people
- Sponsor
- Neurocrine Biosciences